# Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer

> **NCT01873833** · PHASE2 · TERMINATED · sponsor: **University of Southern California** · enrollment: 10 (actual)

## Conditions studied

- HER2-positive Breast Cancer
- Recurrent Breast Cancer
- Stage IV Breast Cancer

## Interventions

- **DRUG:** capecitabine
- **DRUG:** cyclophosphamide
- **DRUG:** lapatinib ditosylate
- **BIOLOGICAL:** trastuzumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01873833
- **Lead sponsor:** University of Southern California
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-07-29
- **Primary completion:** 2021-03-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Insufficient accrual
- **Last updated:** 2023-10-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873833, "Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01873833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*